Evidence mapPaperPMID 35892913Full record

ReviewLife (Basel, Switzerland)2022

Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment.

Sabina Andreea Leancă, Daniela Crișu, Antoniu Octavian Petriș, Irina Afrăsânie, Antonia Genes, Alexandru Dan Costache, Dan Nicolae Tesloianu, Irina Iuliana Costache

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 6 pooled it
22.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 6 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Triple Antithrombotic Therapy vs Dual Antiplatelet for Prevention of Left Ventricular Thrombus After Anterior Myocardial Infarction: An Updated Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sabina Andreea LeancăDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Daniela CrișuDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Antoniu Octavian PetrișDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Irina AfrăsânieDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Antonia GenesDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Alexandru Dan CostacheDepartment of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Str. University nr. 16, 700083 Iasi, Romania.ORCID 0000-0001-8544-9904
Dan Nicolae TesloianuDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.ORCID 0000-0002-1007-3022
Irina Iuliana CostacheDepartment of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", Bd. Independentei nr. 1, 700111 Iasi, Romania.
Spitalul Clinic Judeţean de Urgenţe "Sf. Spiridon" Iaşi · ROGrigore T. Popa University of Medicine and Pharmacy · ROClinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an incidence relatively high in developed countries and rapidly growing in developing countries. The most common cause of MI is the rupture of an atherosclerotic plaque with subsequent thrombotic occlusion in the coronary circulation. This causes cardiomyocyte death and myocardial necrosis, with subsequent inflammation and fibrosis. Current therapies aim to restore coronary flow by thrombus dissolution with pharmaceutical treatment and/or intravascular stent implantation and to counteract neurohormonal activation. Despite these therapies, the injury caused by myocardial ischemia leads to left ventricular remodeling; this process involves changes in cardiac geometry, dimension and function and eventually progression to heart failure (HF). This review describes the pathophysiological mechanism that leads to cardiac remodeling and the therapeutic strategies with a role in slowing the progression of remodeling and improving cardiac structure and function.

Indexed as

heart failureinflammationleft ventricular remodelingmyocardial infarctionneurohormonal activationwall stress

Identifiers

PMID35892913
PMCPMC9332014
OpenAlexW4287009710

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.